Consequences of acute myelogenous leukemia in early pregnancy.
Cytarabine and thioguanine therapy for acute myelomonocytic leukemia initiated in the tenth week of pregnancy (with the addition of vincristine and rubidomycin at 17 weeks) led to a short complete remission of the leukemia in a 24-year-old primigravida. This is the first case to be reported in which cytarabine was administered in the first trimester and a prostaglandin termination of pregnancy performed at 20 weeks produced an apparently normal fetus. A review of the literature suggests a slightly less than 50% chance of producing a live healthy baby if acute myelogenous leukemia is diagnosed in the first half of pregnancy, with materna mortality approaching 100% by six months postpartum. Current therapy may improve these figures.
D000032:Abortion, Therapeutic; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007226:Infant Mortality; D007231:Infant, Newborn; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000401:mortality; D015470:Leukemia, Myeloid, Acute / Q000150:complications*; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy* / Q000401:mortality; D011261:Pregnancy Trimester, First; D011262:Pregnancy Trimester, Second; D012306:Risk; D013723:Teratogens; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013723:Teratogens; D003561:Cytarabine; D014750:Vincristine; D013866:Thioguanine; D003630:Daunorubicin